Abstract
In an assessment of the immunosuppressive efficacy of FK-506 following corneal allograft transplant surgery preceded subconjunctival injection of either FK-506 or Ciclosporin (CYA) eye drops and topical administration of both FK-506 and CYA.
For FK-506, survival rates were as follows : exchange keratoplasties (0.1mg/Kg twice a week), 100% at 100 days ; re-keratoplasties (0.1mg/Kg twice a week), 88% at 100 days ; and exchange keratoplasties (0.01mg/Kg once a week), 100% at 200 days.
For CYA, survival rate exchange keratoplasties (0.025% 4 times a day) was 100% at 100 days, and that of re-keratoplasties (0.025% 4 times a day) was 66% at 40 days. Even topical administration of FK-506 and CYA together suppressed allograft rejection of experimental keratoplasties. We found that topical administration of FK-506 and CYA may be an effective immunosuppressant in clinical keratoplasties.
